There are new and promising treatments that have been discovered to help those who have ovarian, prostate or breast cancer. Most of us know someone who has been affected by cancer. These breakthroughs give hope that one day their may be a cure or vaccination for cancer.
Prostate cancer is the second most deadly cancer among men. Approximately 192,280 men are diagnosed with prostate cancer each year. There is a new treatment that is promising to those who have prostate cancer. Once a prostate tumor reaches a certain size it becomes increasingly difficult to remove, and leaves few options for treatments. Missouri researchers discovered a new treatment using engineered radioactive gold nanoparticles that reduce cancerous prostate tumors in mice. Investigators Kattesh Katti, PhD, Raghuraman Kannan, PhD and the University of Missouri’s Medicine Department have been studying this for four years, and are now in the process of applying to perform this treatment on humans. Researchers discovered that there was an unprecedented 82 percent reduction in tumor volume affected by only one dose of the radioactive gold nanoparticles. Researchers found this treatment to have limited or no side effects as a result of the injected dose.
Ovarian cancer is the eighth most common cancer among women, and the 5th most common cancer. Researchers have discovered a promising new treatment for those in advance stages of ovarian cancer. They found adding Avastin to the basic chemotherapy for women with advanced ovarian cancer, followed by continual maintenance doses of the drug afterwards, greatly extended the patient’s survival. Avastin, a human monoclonal antibody, limits the tumor growth by blocking the formation of the new blood vessels to supply the cancerous tumor with needed nutrients. Before this breakthrough, they could only treat ovarian cancer with surgery and chemotherapy, which involves toxic agents. This third treatment option gives hope to those with advanced ovarian cancer. This trial was presented at the Annual Meeting of American Society of Clinical Oncology.
Researchers have a promising first vaccine to prevent breast cancer. This vaccine would be for women 40 and over, and those with a high risk of breast cancer. Researchers at the Cleveland Clinic’s Lerner Research Institute conducted a study of the first one-of-a-kind vaccine to prevent breast cancer. This study has shown overwhelmingly positive results in animal models. This study found that a single vaccination with the antigen a-lactalbumin prevents breast cancer tumors from developing in mice. It also has shown that it inhibited the growth of cancerous tumors that already existed. Human trials could begin as early as next year. If successful, this would be the first vaccine to prevent breast cancer. In the study, genetically cancer-prone mice were vaccinated. Half of the mice were vaccinated with one a-lactalbumin vaccine and the other mice were vaccinated with a vaccine that didn’t contain antigen. The mice vaccinated with antigen didn’t develop breast cancer, and the mice injected without this all got cancer.
For more information on promising cancer treatments go to www.ivanhoe.com, www.missouri.edu, and www.lerner.ccf.org.